Thursday, June 11, 2026
RSS

Inside BCI

Brain-Computer Interface Industry News
Industry News Research Policy Opinion Market Moves
About Directory Glossary

Tag: neuralink

9 articles

Policy & Regulation

Neuralink hires its first federal lobbyists to open the brain-computer interface coverage account

Newly filed federal disclosures show that Neuralink has engaged Jeffrey J. Kimbell & Associates and Arnold & Porter Kaye Scholer as its first registered federal lobbyists, with both firms beginning work at the end of April 2026. The scope explicitly names brain-computer interface development and commercialisation plus 'coverage of such devices' as the lobbying focus. The team on the Arnold & Porter side includes former 13-term Wisconsin Democratic Rep. Ron Kind, Senior Counsel at the firm since January 2024 and a former House Ways and Means Committee member overseeing Medicare payment programs. The hire is the first publicly visible step Neuralink has taken toward US Medicare reimbursement positioning for the N1 implant.

Jun 3

Industry News

Irish patient with motor neurone disease uses his Neuralink brain implant to steer his wheelchair with thoughts alone

Eoin Egan, a 43-year-old Roscommon-born architect and property consultant living in London with motor neurone disease, has gone public as one of seven UK participants in Neuralink's GB-PRIME early feasibility study. Egan received his N1 Implant in December 2025 at UCLH's National Hospital for Neurology and Neurosurgery (Queen Square) in a six-hour robot-performed operation. Four days post-surgery he was driving his wheelchair through a London park with his thoughts alone, using bespoke software built by German assistive technology firm Homebrace that links the BCI cursor to wheelchair steering. He is the third UK GB-PRIME participant to surface publicly, after Paul (October 2025, also MND) and Sebastian Gomez (medical student paralysed in a diving accident).

May 31

Industry News

Neuralink's surgical robot can now reach any region of the human brain, opening Parkinson's, epilepsy and depression as new target indications

Neuralink disclosed on 7 May 2026 that its next-generation R1 surgical robot can place electrode threads into virtually any region of the human brain, threading through the dura mater with real-time motion compensation and a suite of eight optical coherence tomography cameras. The scope expansion opens Parkinson's disease, refractory epilepsy, and treatment-resistant depression as new target indications beyond motor-function restoration.

May 22